Table 3

Unadjusted and adjusted* HR’s for mortality between 1980 and 2013 from all-causes, cardiovascular disease, cancer, and breast cancer in the groups given folic acid supplements in the Aberdeen folic acid supplementation trial, 1966–1967

nUnadjusted HR (95% CI; p value)p For trendAdjusted HR* (95% CI; p value)p For trend
Mortality risk in the two separate supplement groups
All-cause mortality
 Placebo2891.000.881.000.22
 0.2 mg folic acid781.16 (0.91 to 1.49; 0.24)1.23 (0.95 to 1.81; 0.12)
 5 mg folic acid700.97 (0.75 to 1.26; 0.82)1.13 (0.86 to 1.48; 0.39)
Cardiovascular mortality
 Placebo691.000.341.000.22
 0.2 mg folic acid130.82 (0.45 to 1.48; 0.50)0.92 (0.51 to 1.68; 0.80)
 5 mg folic acid231.35 (0.84 to 17; 0.21)1.45 (0.87 to 2.41; 0.15)
All cancer deaths
 Placebo1321.000.621.000.69
 0.2 mg folic acid361.17 (0.81 to 1.69; 0.41)1.30 (0.89 to 1.90; 0.18)
 5 mg folic acid270.84 (0.55 to 1.27; 0.40)1.00 (0.65 to 1.52; 0.99)
Breast cancer mortality
 Placebo361.000.771.000.61
 0.2 mg folic acid80.95 (0.44 to 2.04; 0.90)0.98 (0.45 to 2.13; 0.96)
 5 mg folic acid101.14 (0.56 to 2.29; 0.72)1.24 (0.61 to 2.51; 0.56)
Mortality risk in the two supplement groups combined 
All-cause mortality
 Placebo2891.001.00
 Supplemented1481.06 (0.87 to 1.29; 0.60)1.17 (0.95 to 1.44; 0.14)
Cardiovascular mortality
 Placebo691.001.00
 Supplemented361.09 (0.73 to 1.63; 0.67)1.18 (0.77 to 1.80; 0.45)
All cancer deaths
 Placebo1321.001.00
 Supplemented630.98 (0.73 to 1.33; 0.91)1.13 (0.82 to 1.54; 0.45)
Breast cancer mortality
 Placebo361.001.00
 Supplemented180.99 (0.55 to 1.76; 0.97)1.05 (0.58 to 1.89; 0.87)
  • *Adjusted for maternal age, smoking, height, weight, social class, parity and gestational age.